Clinical trial
Treatment for First-Episode Schizophrenia
NCT00000374 · Northwell Health, Other · Completed
Key facts
| NCT number | NCT00000374 |
|---|---|
| Title | Treatment for First-Episode Schizophrenia |
| Official title | Preventing Morbidity in First-Episode Schizophrenia |
| Lead sponsor | Northwell Health, Other |
| Collaborators | National Institute of Mental Health (NIMH) NIH The Zucker Hillside Hospital |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Olanzapine, Risperidone |
| Enrollment | 125 |
| Start date | Sep 1, 1998 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Nov 3, 1999 |
| Last update posted | Jan 13, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: